Home Healthcare Pharmaceuticals Rapid-Acting Insulin Market

Rapid-Acting Insulin Market Size, Share & Trends Analysis Report By Product Type (Insulin Lispro, Insulin Aspart, Insulin Glulisine), By Disease (Type 1 Diabetes, Type 2 Diabetes), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Provider) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Debashree B | Format: | Report Code: SR2033DR | Pages: 110
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Rapid-Acting Insulin Market, By Product Type 2022-2034 (USD MILLION/ Units)
    1. Insulin Lispro
    2. Insulin Aspart
    3. Insulin Glulisine
  2. Rapid-Acting Insulin Market, By Disease 2022-2034 (USD MILLION/ Units)
    1. Type 1 Diabetes
    2. Type 2 Diabetes
  3. Rapid-Acting Insulin Market, By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. Online Provider
  4. Regional Rapid-Acting Insulin Market
    1. North America
      1. North America Rapid-Acting Insulin Market By Product Type 2022-2034 (USD MILLION/ Units)
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
      2. North America Rapid-Acting Insulin Market By Disease 2022-2034 (USD MILLION/ Units)
        1. Type 1 Diabetes
        2. Type 2 Diabetes
      3. North America Rapid-Acting Insulin Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Provider
      4. U.S.
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
        4. Type 1 Diabetes
        5. Type 2 Diabetes
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Online Provider
      5. Canada
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
        4. Type 1 Diabetes
        5. Type 2 Diabetes
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Online Provider
    2. Europe
      1. Europe Rapid-Acting Insulin Market By Product Type 2022-2034 (USD MILLION/ Units)
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
      2. Europe Rapid-Acting Insulin Market By Disease 2022-2034 (USD MILLION/ Units)
        1. Type 1 Diabetes
        2. Type 2 Diabetes
      3. Europe Rapid-Acting Insulin Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Provider
      4. U.K.
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
        4. Type 1 Diabetes
        5. Type 2 Diabetes
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Online Provider
      5. Germany
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
        4. Type 1 Diabetes
        5. Type 2 Diabetes
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Online Provider
      6. France
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
        4. Type 1 Diabetes
        5. Type 2 Diabetes
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Online Provider
      7. Spain
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
        4. Type 1 Diabetes
        5. Type 2 Diabetes
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Online Provider
      8. Italy
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
        4. Type 1 Diabetes
        5. Type 2 Diabetes
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Online Provider
      9. Russia
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
        4. Type 1 Diabetes
        5. Type 2 Diabetes
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Online Provider
      10. Nordic
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
        4. Type 1 Diabetes
        5. Type 2 Diabetes
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Online Provider
      11. Benelux
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
        4. Type 1 Diabetes
        5. Type 2 Diabetes
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Online Provider
      12. Rest of Europe
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
        4. Type 1 Diabetes
        5. Type 2 Diabetes
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Online Provider
    3. APAC
      1. APAC Rapid-Acting Insulin Market By Product Type 2022-2034 (USD MILLION/ Units)
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
      2. APAC Rapid-Acting Insulin Market By Disease 2022-2034 (USD MILLION/ Units)
        1. Type 1 Diabetes
        2. Type 2 Diabetes
      3. APAC Rapid-Acting Insulin Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Provider
      4. China
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
        4. Type 1 Diabetes
        5. Type 2 Diabetes
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Online Provider
      5. Korea
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
        4. Type 1 Diabetes
        5. Type 2 Diabetes
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Online Provider
      6. Japan
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
        4. Type 1 Diabetes
        5. Type 2 Diabetes
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Online Provider
      7. India
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
        4. Type 1 Diabetes
        5. Type 2 Diabetes
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Online Provider
      8. Australia
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
        4. Type 1 Diabetes
        5. Type 2 Diabetes
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Online Provider
      9. Taiwan
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
        4. Type 1 Diabetes
        5. Type 2 Diabetes
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Online Provider
      10. South East Asia
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
        4. Type 1 Diabetes
        5. Type 2 Diabetes
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Online Provider
      11. Rest of Asia-Pacific
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
        4. Type 1 Diabetes
        5. Type 2 Diabetes
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Online Provider
    4. Middle East and Africa
      1. Middle East and Africa Rapid-Acting Insulin Market By Product Type 2022-2034 (USD MILLION/ Units)
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
      2. Middle East and Africa Rapid-Acting Insulin Market By Disease 2022-2034 (USD MILLION/ Units)
        1. Type 1 Diabetes
        2. Type 2 Diabetes
      3. Middle East and Africa Rapid-Acting Insulin Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Provider
      4. UAE
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
        4. Type 1 Diabetes
        5. Type 2 Diabetes
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Online Provider
      5. Turkey
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
        4. Type 1 Diabetes
        5. Type 2 Diabetes
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Online Provider
      6. Saudi Arabia
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
        4. Type 1 Diabetes
        5. Type 2 Diabetes
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Online Provider
      7. South Africa
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
        4. Type 1 Diabetes
        5. Type 2 Diabetes
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Online Provider
      8. Egypt
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
        4. Type 1 Diabetes
        5. Type 2 Diabetes
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Online Provider
      9. Nigeria
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
        4. Type 1 Diabetes
        5. Type 2 Diabetes
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Online Provider
      10. Rest of MEA
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
        4. Type 1 Diabetes
        5. Type 2 Diabetes
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Online Provider
    5. LATAM
      1. LATAM Rapid-Acting Insulin Market By Product Type 2022-2034 (USD MILLION/ Units)
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
      2. LATAM Rapid-Acting Insulin Market By Disease 2022-2034 (USD MILLION/ Units)
        1. Type 1 Diabetes
        2. Type 2 Diabetes
      3. LATAM Rapid-Acting Insulin Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Provider
      4. Brazil
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
        4. Type 1 Diabetes
        5. Type 2 Diabetes
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Online Provider
      5. Mexico
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
        4. Type 1 Diabetes
        5. Type 2 Diabetes
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Online Provider
      6. Argentina
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
        4. Type 1 Diabetes
        5. Type 2 Diabetes
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Online Provider
      7. Chile
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
        4. Type 1 Diabetes
        5. Type 2 Diabetes
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Online Provider
      8. Colombia
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
        4. Type 1 Diabetes
        5. Type 2 Diabetes
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Online Provider
      9. Rest of LATAM
        1. Insulin Lispro
        2. Insulin Aspart
        3. Insulin Glulisine
        4. Type 1 Diabetes
        5. Type 2 Diabetes
        6. Hospital Pharmacies
        7. Drug Stores & Retail Pharmacies
        8. Online Provider
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.